Compare AbCellera Biologics Inc (ABCL) vs Tidewater Inc (TDW) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Tidewater (TDW) trades at $68.19, up 0.1% on the day, with a mixed technical picture showing bullish overall signals but bearish moving averages. Recent earnings misses in Q1 2026 and Q4 2025 contrast with strong 2025 profitability, including a 22.16% net income margin and 24.03% ROE. The company reported $1.35B revenue in 2025, with net income of $334.66M, though 2026 projections indicate a slight decline. Positive cash flow from operations of $379.11M in 2025 supports financial health, while analyst sentiment remains cautious with a 'Hold' consensus.

Outlook: TDW's valuation appears reasonable with a P/E of 11.5 and EV/EBITDA of 8.52, but recent earnings volatility and a 61.54% analyst hold rating suggest near-term headwinds. Key risks include execution challenges amid declining revenue projections and competitive pressures in offshore marine services. Upside potential hinges on improved earnings consistency and sector recovery, while downside risks involve further profit margin compression and macroeconomic sensitivity.